protocolSection identificationModule nctId: NCT06297122, orgStudyIdInfo id: APHP240002, briefTitle: Severe Group A Streptococcus Infections in Paris, France, 2018-2023, acronym: IGASI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses.In several European countries and the United States, a notable surge in invasive GAS (iGAS) infections has been documented since mid-2022. This sharp increase contrasts with the gradual rise in iGAS incidence observed among children over the past three decades. As demonstrated for several viral infections, the recent upturn in iGAS infections is potentially linked to the relaxation of mitigation measures implemented during the COVID-19 pandemic, such as face mask usage and school closures.Since November 2022, concerns have been raised by French public health authorities regarding the rise in levels of iGAS infections, and an unexpected increase in pediatric severe GAS infections was reported in a French single-center study. However, this study ended in December 2022 and could only explore short-term trends. The Necker - Enfants malades Hospital in Paris, France, represents an excellent opportunity to examine the impact of the COVID-19 pandemic and the associated non-pharmaceutical interventions on the incidence of severe GAS infections, during, and after the pandemic.This study aims to investigate trends of severe GAS infection incidence in children in the Paris area over the course of the COVID-19 pandemic., conditionsModule conditions: Invasive Group A Beta-Haemolytic Streptococcal Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Collection of data from the patient's medical file, outcomesModule primaryOutcomes measure: Monthly incidence of severe Group A Streptococcus (GAS) infections per 1000 pediatric hospital admissions, secondaryOutcomes measure: Age of children age with group A Streptococcus (GAS) infections, secondaryOutcomes measure: Proportion of children needing surgical intervention for the management of GAS infection, secondaryOutcomes measure: Proportion of cases admitted in the PICU for GAS infection, secondaryOutcomes measure: Proportion of deaths from GAS infection, secondaryOutcomes measure: Hospital length of stay for the management of GAS infection, secondaryOutcomes measure: Distribution of infection type of GAS infection, secondaryOutcomes measure: Proportion of healthcare-associated infections during the management of GAS infection, eligibilityModule sex: ALL, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Hôpital Necker-Enfants Malades, city: Paris, zip: 75015, country: France, contacts name: Jérémie Cohen, M.D., PhD, role: CONTACT, phone: 1 44 49 48 72, phoneExt: +33, email: jeremie.cohen2@aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False